{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:09:50Z","timestamp":1790075390287,"version":"4.0.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["RRCT"],"published-print":{"date-parts":[[2026,9,18]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The introduction of biosimilars into the marketplace has allowed more patients access to\nbiological drugs through the development of alternative, but highly similar biological products.\nHowever, the complex nature of biosimilars in terms of structure, manufacture, and risk of immunogenicity\nrequires strong and continual pharmacovigilance throughout the lifecycle of these biological\nproducts. The present review seeks to offer a comprehensive insight into existing pharmacovigilance\npractices for biosimilars, with a particular focus on immunogenicity, post-market surveillance, real-world\nevidence, digital technology, traceability, and regulatory practices. A narrative review was\nperformed on relevant literature identified from PubMed, Scopus, Web of Science, and Google\nScholar, alongside guidance and regulation on biosimilar pharmacovigilance from relevant regulatory\nagencies. This review indicates that successful pharmacovigilance for biosimilars necessitates the\nuse of an approach that combines spontaneous adverse event reporting, active post-market surveillance,\nimmunogenicity evaluation, real-world evidence, risk management, and product traceability.\nNovel strategies using artificial intelligence, machine learning, digital health tools, blockchain technology\nfor traceability, and pharmacoepidemiology could enhance signal detection, better understand\nproduct identification, conduct long-term safety evaluations, and implement risk management.\nThere still exist several challenges connected with data quality, interoperability, confidentiality, infrastructure,\nharmonization of regulations, and standardized approaches to biosimilar safety monitoring.\nThus, an active, lifecycle-based pharmacovigilance system that integrates immunogenicity surveillance,\nreal-world evidence, digital technologies, and standardized regulation is essential for improved\nbiosimilar pharmacovigilance and clinical use of biosimilars.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115748871503065260901071735","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:57:57Z","timestamp":1790074677000},"source":"Crossref","is-referenced-by-count":0,"title":["Proactive Safety Monitoring of Biosimilars: A Comprehensive Approach\nCombining Immunogenicity, Big Data, and Global Standards"],"prefix":"10.2174","volume":"21","author":[{"given":"Megha","family":"Naudiyal","sequence":"first","affiliation":[{"name":"School of Pharmacy &amp; Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzoo","family":"Pannu","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivang","family":"Gangotri","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utkarsh","family":"Kumar","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny Kumar","family":"Rao","sequence":"additional","affiliation":[{"name":"School of Pharmacy &amp; Research, Dev Bhoomi Uttarakhand University, Dehradun, 248007, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Reviews on Recent Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871503065260901071735","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/258506\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748871503065260901071735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:57:57Z","timestamp":1790074677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/258506\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748871503065260901071735","relation":{},"ISSN":["1574-8871"],"issn-type":[{"value":"1574-8871","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}